Annual CFF
$28.44 M
+$28.42 M+149590.00%
December 31, 2023
Summary
- As of February 8, 2025, IMRX annual cash flow from financing activities is $28.44 million, with the most recent change of +$28.42 million (+149590.00%) on December 31, 2023.
- During the last 3 years, IMRX annual CFF has fallen by -$9.54 million (-25.12%).
- IMRX annual CFF is now -80.29% below its all-time high of $144.26 million, reached on December 31, 2021.
Performance
IMRX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$4.36 M
+$4.36 M+100.00%
September 30, 2024
Summary
- As of February 8, 2025, IMRX quarterly cash flow from financing activities is $4.36 million, with the most recent change of +$4.36 million (+100.00%) on September 30, 2024.
- Over the past year, IMRX quarterly CFF has increased by +$3.38 million (+345.41%).
- IMRX quarterly CFF is now -96.32% below its all-time high of $118.49 million, reached on September 30, 2021.
Performance
IMRX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$5.35 M
+$4.34 M+430.40%
September 30, 2024
Summary
- As of February 8, 2025, IMRX TTM cash flow from financing activities is $5.35 million, with the most recent change of +$4.34 million (+430.40%) on September 30, 2024.
- Over the past year, IMRX TTM CFF has dropped by -$23.83 million (-81.66%).
- IMRX TTM CFF is now -97.05% below its all-time high of $181.24 million, reached on September 30, 2021.
Performance
IMRX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
IMRX Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +10000.0% | +345.4% | -81.7% |
| 3 y3 years | -25.1% | +2463.1% | +10000.0% |
| 5 y5 years | +65.6% | +2463.1% | +10000.0% |
IMRX Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -80.3% | >+9999.0% | -84.5% | +2463.1% | -96.3% | >+9999.0% |
| 5 y | 5-year | -80.3% | >+9999.0% | -96.3% | +2463.1% | -97.0% | >+9999.0% |
| alltime | all time | -80.3% | >+9999.0% | -96.3% | +2463.1% | -97.0% | >+9999.0% |
Immuneering Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $4.36 M(>+9900.0%) | $5.35 M(+430.4%) |
| Jun 2024 | - | $0.00(-100.0%) | $1.01 M(-96.5%) |
| Mar 2024 | - | $979.90 K(>+9900.0%) | $29.18 M(+2.6%) |
| Dec 2023 | $28.44 M(>+9900.0%) | $7800.00(-63.6%) | $28.44 M(+0.7%) |
| Sep 2023 | - | $21.40 K(-99.9%) | $28.25 M(+0.1%) |
| Jun 2023 | - | $28.17 M(>+9900.0%) | $28.21 M(>+9900.0%) |
| Mar 2023 | - | $239.40 K(-229.6%) | $65.30 K(+243.7%) |
| Dec 2022 | $19.00 K | -$184.70 K(+973.8%) | $19.00 K(-91.0%) |
| Sep 2022 | - | -$17.20 K(-161.9%) | $211.20 K(-99.8%) |
| Jun 2022 | - | $27.80 K(-85.6%) | $118.72 M(-17.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $193.10 K(+2474.7%) | $144.46 M(+0.1%) |
| Dec 2021 | $144.26 M(+279.8%) | $7500.00(-100.0%) | $144.26 M(-20.4%) |
| Sep 2021 | - | $118.49 M(+359.8%) | $181.24 M(+188.8%) |
| Jun 2021 | - | $25.77 M(>+9900.0%) | $62.75 M(+69.7%) |
| Mar 2021 | - | $0.00(-100.0%) | $36.98 M(-2.6%) |
| Dec 2020 | $37.98 M(+121.2%) | $36.98 M(>+9900.0%) | $37.98 M(+3704.7%) |
| Sep 2020 | - | $0.00(0.0%) | $998.30 K(0.0%) |
| Jun 2020 | - | $0.00(-100.0%) | $998.30 K(0.0%) |
| Mar 2020 | - | $998.30 K | $998.30 K |
| Dec 2019 | $17.17 M | - | - |
FAQ
- What is Immuneering annual cash flow from financing activities?
- What is the all time high annual CFF for Immuneering?
- What is Immuneering annual CFF year-on-year change?
- What is Immuneering quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Immuneering?
- What is Immuneering quarterly CFF year-on-year change?
- What is Immuneering TTM cash flow from financing activities?
- What is the all time high TTM CFF for Immuneering?
- What is Immuneering TTM CFF year-on-year change?
What is Immuneering annual cash flow from financing activities?
The current annual CFF of IMRX is $28.44 M
What is the all time high annual CFF for Immuneering?
Immuneering all-time high annual cash flow from financing activities is $144.26 M
What is Immuneering annual CFF year-on-year change?
Over the past year, IMRX annual cash flow from financing activities has changed by +$28.42 M (+149590.00%)
What is Immuneering quarterly cash flow from financing activities?
The current quarterly CFF of IMRX is $4.36 M
What is the all time high quarterly CFF for Immuneering?
Immuneering all-time high quarterly cash flow from financing activities is $118.49 M
What is Immuneering quarterly CFF year-on-year change?
Over the past year, IMRX quarterly cash flow from financing activities has changed by +$3.38 M (+345.41%)
What is Immuneering TTM cash flow from financing activities?
The current TTM CFF of IMRX is $5.35 M
What is the all time high TTM CFF for Immuneering?
Immuneering all-time high TTM cash flow from financing activities is $181.24 M
What is Immuneering TTM CFF year-on-year change?
Over the past year, IMRX TTM cash flow from financing activities has changed by -$23.83 M (-81.66%)